Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev Cardiovasc Ther. 2011; 9 :279–286.Paikin JS, Haroun MJ, Eikelboom JW (2011) Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev Cardiovasc Ther 9:279-286...
Safety and Effectiveness of Dabigatran in Atrial Fibrillation in a Real-World PopulationMitral stenosisStrokeSurgeryHeart failure constitutes an important medical, social and economic problem. The prevalence of heart failure is estimated as 2-3% of the adult population and increases with age, despite ...
The use of PRADAXA for the prophylaxis of thromboembolic events in patients with atrial fibrillation in the setting of other forms of valvular heart disease, including the presence of a bioprosthetic heart valve, has not been studied and is not recommended. Effect Of P-gp Inducers And Inhibitors ...
dabigatran is used when the atrial fibrillation is not caused by a heart valve problem.Dabigatran may also be used for purposes not listed in this medication guide.Dabigatran side effectsGet emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of ...
AHA/ACC/HRS guidelines for atrial fibrillation Class 1: For patients with AF or atrial flutter <48-hour duration and with high risk of stroke, IV heparin or LMWH, or administration of a factor Xa or direct thrombin inhibitor, is recommended as soon as possible before or immediately after car...
(for the prevention of thromboembolic stroke in chronic atrial fibrillation) [8]. However, the prolongation of the ECT is directly and linearly related to the plasmatic levels of dabigatran. Thus, ECT may be considered as the future test of choice for the clinical monitoring of the effect of...
Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and stroke in people with atrial fibrillation. Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It...
[摘要] Dabigatran etexilate 是一种新型口服抗凝药物,通过直接抑制凝血酶起到抗凝作用。该药在预防静脉血栓栓塞症(venous thr omboe mbolis m ,VTE )中已完成Ⅲ期临床试验,治疗急性VTE 和心房颤动(atrial fibrillati on,AF )的预防正在进行Ⅲ期临床试验。2008年3月,欧盟已批准其在欧盟27个成员国上市。现对 ...
Introduction and objectives Assessment of the cost-effectiveness of dabigatran for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in Spain, from the perspective of the National Health System. Methods Adaptation of a Markov chain model that simulates the...
Uses for DabigatranEmbolism Associated with Atrial FibrillationReduction in risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.Direct oral anticoagulants (DOACs; apixaban, dabigatran, edoxaban, rivaroxaban) are noninferior or superior to warfarin in reducing ...